COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
The Food and Drug Administration Aug. 22 granted emergency use authorization for two new combined COVID-19 and influenza tests.
The Centers for Disease Control COVID-19 data tracker shows an 18.1% test positivity rate for the week ending Aug. 10, the highest it has been since January 2022.
The Centers for Disease Control and Prevention Aug. 13 issued an advisory alerting of an uptick of cases of parvovirus B19 across the U.S.
A tool designed for EVS workers to find resources/trainings aligned with AHE's competencies in order to identify resources across all job levels.
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25.
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced.
The Food and Drug Administration’s independent Nonprescription Drugs Advisory Committee Sept. 12 by unanimous vote declared oral phenylephrine ineffective as a decongestant.
The Senate Health, Education, Labor and Pensions Committee voted 17-3 to pass as amended the Pandemic and All-Hazards Preparedness and Response Act (S. 2333), which would reauthorize the Hospital Preparedness Program at the current funding level of $385 million through fiscal year 2029.
The Food and Drug Administration’s vaccine advisory committee June 15 voted unanimously to recommend updating the current COVID-19 vaccine composition for fall to a monovalent vaccine based on an XBB variant of the virus.
The first data on the safety of a third mRNA COVID-19 vaccine dose among young children show that a third dose is safe for children ages 6 months to 5 years old, similar to findings for doses one and two.